RIGLRigel Pharmaceuticals, Inc.
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -86% · now 4% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RIGL take a bad year?
Rigel Pharmaceuticals, Inc. holds $55M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Debt / equity
- 0.09×
Debt / equity
- Annualised volatility
- 71%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $40M
- Cash and short-term investments
- $95M
- Net cash
- $55M
- EBITDA, trailing twelve months
- $90M
- Operating profit, trailing twelve months
- $87M
- Debt / equity
- 0.09×
- Total debt / EBITDA
- 0.45×
- Annualised volatilitytwo years of daily moves
- 71%
- Worst drawdown on file
- −86%
- Below its 52-week high
- 4.3%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.